Latest news with #Asia-PacificBiopharmaExcellenceAwards
Yahoo
27-05-2025
- Business
- Yahoo
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
SYDNEY, May 27, 2025--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister's visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. "Novotech is a fantastic success story demonstrating the global value of NSW's strengths in life sciences and clinical trials," said Minister Chanthivong. "I was thrilled to learn about Novotech's growth in the Republic of Korea and the central role their business plays in bringing Korean biotech innovation to the world. Investment NSW looks forward to continuing to support Novotech as it generates export dollars for our state while helping people around the world tackle serious health issues." Minister Chanthivong was joined by a delegation including: Brooke O'Rourke, Chief of Staff to Minister Chanthivong. Rebecca McPhee, Deputy Secretary of Investment NSW. David Lawson, NSW Trade & Investment Commissioner for Japan & Korea. Yoojin Kim, NSW Trade & Investment Director for Korea. The delegation engaged with Novotech leaders Dr. Yooni Kim, Hyun Kim, and Lilian Kim, who shared insights into Novotech's growth as a global clinical research organization and the expanding role of South Korea as a premier destination for clinical trials. "We are honored that the Australian NSW Trade Minister and senior officials from NSW Investment have selected Novotech as a leading example of collaboration between Australia and South Korea," said Dr. Yooni Kim, Managing Director – Asia-Pacific at Novotech. "This visit reinforces the strong and growing partnership between the two countries in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, Novotech is committed to creating more success stories that demonstrate the value of this collaboration. I believe Novotech's strong partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market." The discussion reinforced Novotech's strong partnership with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increasing interest from Korean biotechs to conduct research in Australia, both parties explored opportunities to enhance bilateral cooperation and accelerate cross-border clinical development. Novotech, recently recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, continues to solidify its position as the region's leading clinical development partner. The company offers Korean biotech sponsors seamless access to Australia's world-class research infrastructure, regulatory expertise, and accelerated clinical pathways. Through its integrated full-service model, Novotech enables Korean biotechs to confidently expand early-phase programs into Australia, backed by deep regional knowledge and globally aligned operational standards. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results For more information or to speak to an expert team member visit View source version on Contacts Media Contact Toyna Chin mediacontact@ USA: +1 415 364 8135 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-03-2025
- Business
- Yahoo
Novotech Named Best Contract Research Organization in Australia at Asia-Pacific Biopharma Excellence Awards 2025
SYDNEY, March 24, 2025--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market, has been recognized as the Best Contract Research Organization in Australia at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2025. Novotech, headquartered in Australia with a global presence across 30+ offices, is not only a global CRO but a leading CRO in the Asia-Pacific region. The Asia-Pacific Biopharma Excellence Awards 2025, which celebrates excellence in clinical trials among others, recognizes organizations, experts, and technologies at the forefront of biopharma innovation. Winners are selected through 100% industry voting, ensuring recognition by industry peers. At the recent Awards event held at the Sands Expo & Convention Center in Singapore, Chris Chong, Senior Director of Clinical Services, accepted the award on behalf of Novotech. In his remarks, Mr. Chong expressed gratitude for the recognition, stating, "We thank the Asia-Pacific Biopharma Excellence Awards for this recognition. This award reflects the dedication of our teams worldwide who support biopharma innovation. Our clients and partners entrust us with their research, and we take pride in accelerating the development of new therapies. Novotech remains committed to advancing clinical research, strengthening partnerships, and maintaining high standards in biopharma development." This recognition further strengthens Novotech's industry leadership, adding to its long-standing achievements, including being named Frost & Sullivan CRO Company of the Year award for 19 consecutive years. For more information on Novotech, visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations. Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years. For more information or to speak to an expert team member visit View source version on Contacts Media: Toyna Chin mediacontact@ North America: +1 415 364 8135 Sign in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
IDBS Awarded Best Bioprocessing Supplier Award: Software, at the Asia-Pacific Biopharma Excellence Awards 2025
WOKING, United Kingdom, March 20, 2025 /PRNewswire/ -- IDBS, a provider of cloud software for BioPharma companies, is thrilled to announce that it has been awarded the Best Bioprocessing Supplier Award: Software, at the prestigious Asia-Pacific Biopharma Excellence Awards (ABEA) 2025. This recognition highlights our outstanding contributions to advancing BioPharma excellence in the Asia-Pacific region. The accolade, determined by the votes of over 10,000 professionals from 500+ entries, 300+ industry leaders, 150+ companies, and 50+ countries in the bioprocessing, logistics and supply chain management, ADC and clinical trials sectors across the Asia-Pacific region, underscores IDBS' significant contribution to digital transformation in the life sciences industry. The Asia-Pacific Biopharma Excellence Awards 2025 seeks to recognize exceptional Asian bioprocessing, logistics and supply chain management, ADC and clinical trials experts, organizations and technologies over the past year. By recognizing outstanding achievements of top BioPharma leaders, the awards applaud extraordinary leaders and trend-setters of today and inspire innovators of tomorrow. "We are incredibly honored to receive this award," said Pietro Forgione, General Manager of IDBS. "This recognition from our industry peers highlights the dedication of our team to advancing digitalization within biologics. We are committed to continuing our efforts to provide innovative solutions that enhance quality and efficiency for our customers." The awards ceremony took place on March 12th at the Sands Expo & Convention Centre, Singapore, in conjunction with the 12th Annual Biologics Manufacturing Asia 2025, the 9th Biologistics World Asia, and the Clinical Trial Festival Asia. This prestigious event brought together over 1300+ industry leaders and pioneers to celebrate significant achievements in the BioPharma sector. Lear more about the award here. About IDBS IDBS helps BioPharma organizations unlock the potential of AI/ML to improve the lives of patients. As a trusted long-term partner to 80% of the top 20 global BioPharma companies1, IDBS delivers powerful cloud software and services specifically designed to meet the evolving needs of the BioPharma sector. IDBS, a Danaher company, leverages 35 years of scientific informatics expertise to help organizations design, execute and orchestrate processes, manage, contextualize and structure data and gain valuable insights throughout the product lifecycle, from R&D through manufacturing. Known for its signature IDBS E-WorkBook software, IDBS has extended its flexible, scalable solutions to the IDBS Polar and PIMS cloud platforms to help scientists make smarter decisions with assured confidence in both GxP and non-GxP environments. Visit to learn more about IDBS. Rank measured by Market Cap, Q1 2024. MEDIA ENQUIRIES e | mediaenquiries@ View original content to download multimedia: SOURCE IDBS Sign in to access your portfolio
Yahoo
13-03-2025
- Business
- Yahoo
WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025
SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, has been honored with four prestigious awards at the Asia-Pacific Biopharma Excellence Awards 2025. The Asia-Pacific Biopharma Excellence Awards honor companies annually that have exhibited outstanding performance and achievement in the biopharmaceutical sector. These accolades underscore WuXi XDC's leadership, innovation, and fully integrated CRDMO platform, empowering global clients from early discovery to commercial manufacturing. Industry-leading development and manufacturing capabilities (Best ADC CDMO in Asia & China): WuXi XDC's state-of-the-art facilities and global dual-sourcing strategy enable seamless CMC development and GMP manufacturing, accelerating the timeline while ensuring a high success rate and regulatory excellence. Innovation in Discovery & Development (Best ADC CRO in Asia): WuXi XDC's proprietary conjugation and payload-linker technologies, along with the incorporation of external technologies through partnerships, drive ADC and XDC discovery, optimization, and IND-enabling studies, expediting clients' clinical advancement. Pioneering ADC Technology (Best ADC Platform Technology): Through next-generation payload-linker innovations and site-specific conjugation technologies, from internal development and external partnership, WuXi XDC provides clients with diversified technology suites to advance ADC and XDC developments. Dr. Jimmy Li, CEO of WuXi XDC, commented: "We are honored to receive these prestigious awards, which not only reaffirm our team's relentless pursuit of excellence and innovation in the ADC field but also underscore our dedication to delivering world-class services that empower our clients to bring novel therapies to patients worldwide. They are a testament to the hard work and dedication of every WuXi XDC employee – their relentless efforts that have made this milestone possible. It also belongs to our valued partners, whose trust and collaboration have driven our collective success. Looking ahead, WuXi XDC will continue to support our clients and advance the innovation and progress of the global bioconjugate industry." These awards follow WuXi XDC's recent recognition at the 2024 World ADC Awards, where the company was named Best CDMO Winner for the second consecutive year, further solidifying its leadership position in the global ADC industry. As the ADC market continues to experience sustainable growth, WuXi XDC relentlessly committed to advancing its technological capabilities and expanding its service offerings to meet clients' evolving needs. About WuXi XDC WuXi XDC Cayman Inc. ("WuXi XDC", stock code: is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: WuXi XDC Contacts Investor: Media: wuxixdc_pr@ BD: wuxixdc_info@ View original content to download multimedia: SOURCE WuXi XDC
Yahoo
13-03-2025
- Business
- Yahoo
Amaran Biotech Wins Asia-Pacific Biopharma Excellence Award 2025
Breakthrough Adjuvant AB-801 Secures 'Bioprocessing Excellence in Taiwan' Honor TAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) -- New-generation Contract Development and Manufacturing Organization (CDMO) Amaran Biotech has been awarded the prestigious 'Bioprocessing Excellence in Taiwan' honor at the Asia-Pacific Biopharma Excellence Awards 2025 ceremony, hosted by renowned consulting firm IMAPAC in Singapore on March 12. Established in 2017, the Asia-Pacific Biopharma Excellence Awards recognize outstanding achievements in bioprocessing, logistics, supply chain management, antibody-drug conjugates (ADC), and clinical trials experts, organizations and technologies across Asia. The awards aim to foster the advancement of the biopharmaceutical industry. Amaran Biotech's high-purity AB-801 adjuvant, produced through its innovative bioprocessing technology, triumphed after a process including nomination, shortlisting, and public voting. An adjuvant is key component added to vaccines to enhance the body's immune response, boosting vaccine efficacy while reducing the required dosage per shot. Amaran Biotech's AB-801 offers application capabilities comparable to the globally recognized adjuvant QS-21, which is derived from the soap bark tree (Quillaja saponaria) native to Chile, Bolivia, and Peru. Saponin-based adjuvants have been utilized in several vaccines, including Shingrix® by GSK for shingles and the Novavax COVID-19 vaccine. Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, stated: 'AB-801 is a GMP-grade QS-21 adjuvant, and we are one of the few CDMOs worldwide capable of manufacturing this product. This honor recognizes our team's dedication and hard work. We will continue to enhance our technologies to deliver high-quality bioprocessing solutions to global clients.' Currently, AB-801 is supplied to a leading pharmaceutical company worldwide, and has been adopted by research institutions and universities across Europe, North America, China, and Japan, as well as vaccine research organizations and manufacturers in China and India. Moving forward, Amaran Biotech will further expand its production capacity and ensure sustainable supply to serve more international clients and drive the global biotech industry Amaran BiotechAmaran Biotech is a CDMO specializing in drug process development, analytical services and cGMP manufacturing of high-value biopharmaceuticals. Amaran Biotech's state-of-the-art manufacturing facility is in the Hsinchu Biomedical Science Park and has been granted the PIC/S GMP certification from the TFDA since 2017. The company has also been audited and fully qualified by the regulatory agencies and third-party auditors from the USA and the EU. For more information, visit Media Contact: Doreen Lin A photo accompanying this announcement is available at in to access your portfolio
